VISIONARY-MS Blinded Interim Data Update Treatment of Visual Pathway Deficits In Chronic Optic Neuropathy for Assessment of Remyelination in Stable RMS H. Beadnall1,A. Klistorner3, M. Barnett3, R. Sergott4, A. Rynders2, K.S. Ho2, M. Mortenson5, R. Glanzman2, M. Hotchkin2 1Sydney Brain Mind Centre and Royal Prince Alfred Hospital, University of Sydney, Australia. 2Clene Nanomedicine, Salt Lake City, UT. 3Sydney Neuroimaging Analysis Centre, Sydney, Australia. 4Annesley EyeBrain Center at Thomas Jefferson University Partnered with Wills Eye Hospital, Philadelphia, PA. 5Clene Nanomedicine, North East, MD. Best Corrected Low Contrast Letter Acuity (OD/OS) Sloan 2.5% Contrast (2 meter) Timed 25-Foot Walk 9-Hole Peg Test (D/ND) Symbol Digit Modalities Test (Cognition) P113 Notes: Mixed Effects Model, Dunnett’s test for multiplicity;  * p<0.05, ** p<0.01, *** p<0.001, **** p<0.0001. Z-Score based on Baseline value for EDSS with ‘Mild’ Severity (e.g., BL Low EDSS [≤1.5]) for each domain. (m)MSFC is the modified MS Functional composite (Low contrast letter acuity (LCLA), 9-hole peg test (9HPT), Timed 25-foot walk (T25FW), and Symbol digit modalities test (SDMT)). All available data in EDC. LCLA (Primary Endpoint) (m)MSFC Secondary Endpoint All Subjects with at least 4 of 6 (m)MSFC Domains by Completed Subject Visit. (m)MSFC domains include LCLA (OS/OD), 9HPT (D/ND), T25FW, SDMT. Design: Randomized Double-Blind Placebo Controlled Trial (1:1:1, 30mg, 15mg, Placebo) Safety: No treatment related SAEs, TEAEs predominantly mild-to-moderate and transient Conclusion: Blinded data show clinically relevant improvements across LCLA & modified-MSFC domains